Fibroblast Growth Factor 19 Improves LPS-Induced Lipid Disorder and Organ Injury by Regulating Metabolomic Characteristics in Mice

Figure 6

Network function analysis and comparison analysis of differential metabolites (DMs) using IPA software. (a, b) Top-ranked enriched networks based on differential metabolites (DMs). Red, significantly increased; green, significantly decreased. (a) LPS vs. control; (b) FGF19 + LPS vs. LPS. (c) Disease and biofunction analysis based on comparison analysis (orange, upregulated; blue, downregulated). Left, LPS vs. control; right, FGF19 + LPS vs. LPS. (d, e) Detailed metabolites related to generation of reactive oxygen species (ROS) in response to LPS. (d) Only LPS treatment. (e) With FGF19 pretreatment (red, significantly increased; green, significantly decreased; orange arrow, activated; blue arrow, inhibited).

(a)

(b)

(c)

(d)

(e)